Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIGRANT GECP 24/02 FMT in Stage II–III NSCLC
2025-521251-24-00Phase 2Authorised
- Sponsor
- Fundación GECP
- Start
- Sep 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab, carboplatin, paclitaxel, rifaximin and fecal microbiome transplant in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fundación GECP. Primary endpoint: Pathological complete response (pCR) rate. Planned start Sep 2025; status: authorised.
02
Drugs
durvalumabcarboplatinpaclitaxelrifaximinfecal microbiome transplant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-521251-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521251-24-00.